Contineum Therapeutics (CTNM) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 173.9% versus a loss of 39.5%. Contineum Therapeutics is the larger company by market cap ($266.4 million vs $260.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | PRLD |
|---|---|---|
| Share price | $7.08 | $3.26 |
| Market cap | $266.36M | $260.16M |
| 1-day change | -10.38% | -1.81% |
| YTD return | -38.06% | +12.41% |
| 1-year return | -39.49% | +173.95% |
| 5-year return | — | -81.39% |
| EPS (TTM) | $-1.73 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $12.14M |
| Revenue growth (YoY) | — | +73.43% |
| Net income (latest FY) | $-59.98M | $-99.50M |
| Operating margin | — | -861.33% |
| Net margin | — | -819.59% |
| 52-week high | $17.79 | $6.83 |
| 52-week low | $6.95 | $1.16 |
| Distance from 52-week high | -60.19% | -52.27% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +212.71% | +182.21% |
| Average volume | 732.62K | 487.98K |
| Shares outstanding | 32.96M | 65.08M |
| Employees | 51 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed CTNM by 213.4 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
CTNM vs PRLD FAQ
Which is bigger, Contineum Therapeutics or Prelude Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $266.36M compared with $260.16M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, CTNM or PRLD?
PRLD returned +173.95% over the past 12 months, compared with -39.49% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.